Você procurou por: vecuronium (Inglês - Maltês)

0.1 mg/kg vecuronium
0.1 mg/kg ta’ vecuronium

n median (minutes) range vecuronium
n medjan (minuti) medda vecuronium

reversal of neuromuscular blockade induced by rocuronium or vecuronium.
it- treġġigħ lura ta ’ imblokk newromuskolari kkaġunat minn rocuronium jew vecuronium.

interactions due to the lasting effect of rocuronium or vecuronium:
interazzjonijiet minħabba l-effett li jdum ta’ rocuronium jew vecuronium:

reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.
it-treġġigħ lura ta’ imblokk newromuskolari kkaġunat minn rocuronium jew vecuronium fl-adulti.

this results in the reversal of neuromuscular blockade induced by rocuronium or vecuronium.
dan jirriżultata fit-treġġigħ lura ta’ l-imblokk newromuskolari kkaġunat minn rocuronium jew vecuronium.

sugammadex has not been investigated in patients receiving rocuronium or vecuronium in the icu setting.
sugammadex ma kienx investigat f’pazjenti li kienu qed jirċievu rocuronium jew vecuronium fi sfond ta’ l-icu.

in another pivotal study patients were randomly assigned to the rocuronium or vecuronium group.
fi studji ieħor importanti ħafna, il-pazjenti kienu assenjati b’mod fortuwitu għall-grupp ta’ rocuronium jew vecuronium.

these are called muscle relaxants, and examples include rocuronium bromide and vecuronium bromide.
dawn huma msejħa rilassanti tal-muskoli, u eżempji jinkludu rocuronium bromide u vecuronium bromide.

sugammadex can be used to reverse different levels of rocuronium or vecuronium induced neuromuscular blockade:
sugammadex jista’ jintuża biex ireġġa’ lura livelli differenti ta’ imblokk newromuskolari kkaġunat minn rocuronium jew vecuronium:

if re-administration of rocuronium or vecuronium is required a waiting time of 24 hours is recommended.
jekk l- għoti mill- ġdid ta ’ rocuronium jew vecuronium ikun meħtieġ, ħin ta ’ stennija ta ’ 24 siegħa hu rrakkomandat.

bridion can be used in adults who have received rocuronium and vecuronium, and in children and adolescents who have received rocuronium.
bridion jista’ jintuża fuq adulti li jkunu ngħataw ir-rokuronju u l-vekuronju, u fuq tfal u adoloxxenti li jkunu ngħataw ir-rokuronju.

please refer to the package leaflet of rocuronium or vecuronium for a list of the specific medicinal products which potentiate neuromuscular blockade.
jekk jogħġbok irreferi għall-fuljett fil-pakkett ta’ rocuronium jew vecuronium għal lista ta’ prodotti mediċinali speċifiċi li jsaħħu l-imblokk newromuskolari.

bridion is not recommended for use in children and adolescents for recovery after vecuronium, or for rapid recovery after any muscle relaxant.
mhuwiex irrakkomandat li bridion jintuża fuq tfal u adoloxxenti għall-irkupru mill-vekuronju jew għal irkupru mgħaġġel wara l-għoti ta’ kwalunkwe rilassant muskolari.

bridion is considered to be a selective relaxant binding agent since it only works with specific muscle relaxants, rocuronium bromide or vecuronium bromide.
bridion huwa kkunsidrat bħala aġent selettiv rilassanti li jwaħħal għaliex dan jaħdem biss ma’ rilassanti speċifiċi tal-muskoli, rocuronium bromide jew vecuronium bromide.

bridion was more effective than neostigmine in reducing the time it took for the muscles to recover, after both moderate and deep muscle relaxation using rocuronium or vecuronium.
bridion kien iżjed effikaċi min-neostigmina fit-tnaqqis ta’ kemm damu il-muskoli biex jirkupraw, wara rilassament tal-muskoli kemm moderat u kemm profond bl-użu tar-rokuronju jew tal-vekuronju.

a dose of 2 mg/kg sugammadex is recommended, if spontaneous recovery has occurred up to at least the reappearance of t2 following rocuronium or vecuronium induced blockade.
doża ta’ 2 mg/kg ta’ sugammadex hi rrakkomandata jekk irkuprar spontanju jkun seħħ sa mill-inqas sad-dehra mill-ġdid ta’ t2 wara imblokk ikkaġunat minn rocuronium jew vecuronium.

this means that it attaches to the muscle relaxants rocuronium and vecuronium forming a ‘complex’ that inactivates the muscle relaxants and stops them having an effect.
dan ifisser li s- sustanza teħel mar-rilassanti muskolari rokuronju u vekuronju u tifforma ‘kumpless’ li jiddiżattiva r- rilassanti muskolari u jwaqqfilhom l-effett.

for toremifene, which has a relatively high binding affinity for sugammadex and for which relatively high plasma concentrations might be present, some displacement of vecuronium or rocuronium from the complex with sugammadex could occur.
għal toremifene, li għandu affinità li jeħel relattivament għolja għal sugammadex u li għalih jistgħu jkunu preżenti konċentrazzjonijiet fil-plażma relattivament għolja, jista’ jseħħ xi spostament ta’ vecuronium jew rocuronium mill-kumpless ma’ sugammadex.

it can be used in adults whenever rocuronium bromide or vecuronium bromide is used and in children and adolescents (aged 2 to 17 years) when rocuronium bromide is used for a moderate level of relaxation.
dan jista’ jintuża fl-adulti kull meta jingħata rocuronium bromide jew vecuronium bromide u fit-tfal u fl-adolexxenti (mill-età ta’ sentejn sa 17-il sena) meta jingħata rocuronium bromide għal livell moderat ta’ rilassament.